Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis

Area of Science:

• Pulmonary Medicine
• Fibrotic Lung Diseases
• Drug Development

Background:

• Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress syndrome (ARDS) with excessive fibroproliferation due to matrix metalloproteinase dysregulation.
• Idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc)-associated interstitial lung disease (ILD) are characterized by activated alveolar epithelial cells and fibroblast activation, with endoplasmic reticulum (ER) stress implicated in pathogenesis.
• These three conditions share overlapping pathological features, suggesting common underlying mechanisms driving lung fibrosis.

Purpose of the Study:

• To explore potential drug development strategies by comparing pathogenic events in COVID-19, IPF, and SSc-ILD.
• To identify similarities and differences in lung fibrosis development across these distinct diseases.
• To highlight the need for further research into the role of antifibrotic therapies for precision medicine approaches.

Main Methods:

• Comparative analysis of the pathogenetic mechanisms underlying lung fibrosis in COVID-19, IPF, and SSc-ILD.
• Review of existing literature and ongoing clinical trials related to fibrotic lung diseases.
• Discussion of potential therapeutic targets and drug development corollaries based on shared pathological pathways.

Main Results:

• Dysregulated matrix metalloproteinases and ER stress are common early events in the pathogenesis of lung fibrosis in COVID-19, IPF, and SSc-ILD.
• Activated alveolar epithelial cells and fibroblasts play crucial roles in the fibrotic response across these conditions.
• The study identifies potential therapeutic avenues by drawing parallels between the diseases.

Conclusions:

• Understanding the shared and distinct pathogenic features of lung fibrosis in post-COVID-19, IPF, and SSc-ILD is crucial for advancing precision medicine.
• Further research is warranted to elucidate the efficacy of antifibrotic agents in managing these fibrotic lung conditions.
• Ongoing clinical trials are expected to provide critical insights into the therapeutic potential of antifibrotics for pulmonary fibrosis.